Drug Policy:

Synribo™ (omacetaxine)

I. PURPOSE

To define and describe the accepted indications for Synribo (omacetaxine) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century Health (NCH) is responsible for processing all medication requests from network ordering providers. Medications not authorized by NCH may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

A. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

1. When health plan Medicaid coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the Preferred Drug Guidelines OR

2. When health plan Exchange coverage provisions—including any applicable PDLs (Preferred Drug Lists)—conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the Preferred Drug Guidelines OR
3. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the Preferred Drug Guidelines shall follow NCH L1 Pathways when applicable, otherwise shall follow NCH drug policies AND
4. Continuation requests of previously approved, non-preferred medication are not subject to this provision AND
5. When available, generic alternatives are preferred over brand-name drugs.

**B. Chronic Myelogenous Leukemia**

1. The member has chronic phase or accelerated phase CML OR is post-transplant AND
2. The member is Philadelphia chromosome or BCR-ABL positive AND
   a. The member has experienced disease progression/intolerance to three or more of the following tyrosine kinase inhibitors: Gleevec (imatinib), Tasigna (nilotinib), Bosulif (bosutinib), or Sprycel (dasatinib) OR
   b. The member has a T315I mutation and has failed Iclusig (ponatinib) to treat CML with this mutation.

**III. EXCLUSION CRITERIA**

A. Disease progression while taking Synribo (omacetaxine).
B. Concurrent use with Gleevec (imatinib), Sprycel (dasatinib), Tasigna (nilotinib), or Bosulif (bosutinib).
C. Dosing exceeds single dose limit of Synribo (omacetaxine) 1.25 mg/m².
D. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

**IV. MEDICATION MANAGEMENT**

A. Please refer to the FDA label/package insert for details regarding these topics.

**V. APPROVAL AUTHORITY**

A. Review – Utilization Management Department
B. Final Approval – Utilization Management Committee

**VI. ATTACHMENTS**

A. None

**VII. REFERENCES**